Target Price | €184.60 |
Price | €139.75 |
Potential | 32.09% |
Number of Estimates | 15 |
15 Analysts have issued a price target Merck 2025 . The average Merck target price is €184.60. This is 32.09% higher than the current stock price. The highest price target is €199.00 42.40% , the lowest is €160.00 14.49% . | |
A rating was issued by 17 analysts: 14 Analysts recommend Merck to buy, 3 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Merck stock has an average upside potential 2025 of 32.09% . Most analysts recommend the Merck stock at Purchase. |
14 Analysts have issued a sales forecast Merck 2024 . The average Merck sales estimate is €21.1b . This is 1.25% higher than the revenue of the last 12 months(TTM). The highest sales forecast is €21.3b 2.13% , the lowest is €21.0b 0.44% .
This results in the following potential growth metrics:
2023 | €21.0b | 5.57% |
---|---|---|
2024 | €21.1b | 0.66% |
2025 | €22.1b | 4.64% |
2026 | €23.1b | 4.52% |
2027 | €24.1b | 4.47% |
2028 | €25.3b | 4.67% |
14 Analysts have issued an Merck EBITDA forecast 2024. The average Merck EBITDA estimate is €6.0b . This is 3.03% lower than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is €6.1b 1.22% , the lowest is €5.8b 6.36% .
This results in the following potential growth metrics and future EBITDA Margins:
2023 | €5.8b | 14.26% |
---|---|---|
2024 | €6.0b | 3.40% |
2025 | €6.5b | 8.18% |
2026 | €7.0b | 6.86% |
2027 | €7.3b | 4.88% |
2028 | €7.8b | 6.20% |
2023 | 27.75% | 9.20% |
---|---|---|
2024 | 28.50% | 2.71% |
2025 | 29.46% | 3.37% |
2026 | 30.13% | 2.27% |
2027 | 30.24% | 0.37% |
2028 | 30.69% | 1.49% |
12 Merck Analysts have issued a net profit forecast 2024. The average Merck net profit estimate is €2.9b . This is 11.12% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is €3.1b 19.21% , the lowest is €2.8b 7.12% .
This results in the following potential growth metrics and future Net Margins:
2023 | €2.8b | 15.03% |
---|---|---|
2024 | €2.9b | 3.26% |
2025 | €3.4b | 17.27% |
2026 | €3.8b | 9.70% |
2027 | €4.1b | 7.90% |
2028 | €4.4b | 9.14% |
2023 | 13.46% | 10.02% |
---|---|---|
2024 | 13.81% | 2.59% |
2025 | 15.48% | 12.09% |
2026 | 16.24% | 4.91% |
2027 | 16.78% | 3.33% |
2028 | 17.50% | 4.29% |
12 Analysts have issued a Merck forecast for earnings per share. The average Merck <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is €6.71 . This is 11.09% higher than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is €7.20 19.21% , the lowest is €6.47 7.12% .
This results in the following potential growth metrics and future valuations:
2023 | €6.50 | 15.03% |
---|---|---|
2024 | €6.71 | 3.23% |
2025 | €7.87 | 17.29% |
2026 | €8.63 | 9.66% |
2027 | €9.32 | 8.00% |
2028 | €10.17 | 9.12% |
Current | 23.14 | 3.06% |
---|---|---|
2024 | 20.82 | 10.03% |
2025 | 17.75 | 14.75% |
2026 | 16.18 | 8.85% |
2027 | 15.00 | 7.29% |
2028 | 13.74 | 8.40% |
Based on analysts' sales estimates for 2024, the Merck stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of 3.26 and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of 2.88 .
This results in the following potential growth metrics and future valuations:
Current | 3.30 | 9.09% |
---|---|---|
2024 | 3.26 | 1.36% |
2025 | 3.11 | 4.43% |
2026 | 2.98 | 4.32% |
2027 | 2.85 | 4.28% |
2028 | 2.72 | 4.46% |
Current | 2.91 | 9.70% |
---|---|---|
2024 | 2.88 | 1.24% |
2025 | 2.75 | 4.44% |
2026 | 2.63 | 4.32% |
2027 | 2.52 | 4.28% |
2028 | 2.40 | 4.46% |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.